Radiopharm Theranostics (RDPTF) Non Operating Interest Expenses (2023 - 2025)
Radiopharm Theranostics' (RDPTF) quarterly Non Operating Interest Expenses came in at -$65300.0 in Q2 2025, up 89.84% year-over-year from -$34396.9 in Q2 2024, and up 89.84% quarter-over-quarter from -$642888.0 in Q2 2024.
Powered by 
Analysis
Radiopharm Theranostics (RDPTF) Non Operating Interest Expenses (2023 - 2025) Analysis & Trends
Radiopharm Theranostics (RDPTF) has reported Non Operating Interest Expenses for 3 consecutive years, with -$65300.0 the latest figure, recorded in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.68 Bn | 197.69 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.84 Bn | 177.66 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.30 Bn | 124.45 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.50 Bn | 74.50 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.49 Bn | 56.31 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 55.01 Bn | 49.87 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.08 Bn | 30.77 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.35 Bn | 30.06 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.87 Bn | 29.87 Bn | 1.16 Mn | - |
| 10 | Radiopharm Theranostics | 23.65 Mn | 23.60 Mn | -92,644.38 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -65,300.00 |
| Jun 30, 2024 | -642,888.00 |
| Jun 30, 2023 | -86,091.00 |